Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by GAMMA Investing LLC

GAMMA Investing LLC cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,985 shares of the medical research company’s stock after selling 866 shares during the period. GAMMA Investing LLC’s holdings in Thermo Fisher Scientific were worth $2,073,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Founders Financial Securities LLC raised its position in shares of Thermo Fisher Scientific by 0.9% during the 2nd quarter. Founders Financial Securities LLC now owns 2,058 shares of the medical research company’s stock worth $1,138,000 after purchasing an additional 19 shares during the period. Foundations Investment Advisors LLC increased its stake in Thermo Fisher Scientific by 4.1% in the 2nd quarter. Foundations Investment Advisors LLC now owns 1,142 shares of the medical research company’s stock worth $632,000 after purchasing an additional 45 shares in the last quarter. Stablepoint Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.8% in the second quarter. Stablepoint Partners LLC now owns 3,901 shares of the medical research company’s stock valued at $2,357,000 after purchasing an additional 179 shares in the last quarter. Commons Capital LLC grew its stake in Thermo Fisher Scientific by 9.0% during the 2nd quarter. Commons Capital LLC now owns 2,405 shares of the medical research company’s stock valued at $1,330,000 after acquiring an additional 199 shares in the last quarter. Finally, FineMark National Bank & Trust increased its stake in Thermo Fisher Scientific by 2.1% in the 2nd quarter. FineMark National Bank & Trust now owns 22,726 shares of the medical research company’s stock valued at $12,567,000 after buying an additional 468 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the sale, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,175,513.68. The trade was a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. The trade was a 13.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,150 shares of company stock valued at $25,954,465 over the last three months. 0.34% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Stifel Nicolaus cut their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Barclays dropped their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Bank of America lowered their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Finally, Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a “buy” rating and a $680.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $650.05.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $522.57 on Friday. The firm has a market cap of $199.88 billion, a price-to-earnings ratio of 32.76, a price-to-earnings-growth ratio of 3.54 and a beta of 0.77. The business has a 50-day simple moving average of $531.16 and a two-hundred day simple moving average of $568.93. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the prior year, the company posted $5.69 EPS. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. On average, analysts expect that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share repurchase program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.30%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.